Tibsovo

Agios sells cancer drug royalty, raising $132M to fund rare disease mission
Agios sells cancer drug royalty, raising $132M to fund rare disease mission
MedCity News
Agios Pharmaceuticals
Tibsovo
Flag link:
ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe
ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe
Fierce Pharma
ASH2021
Servier
Tibsovo
AML
Flag link:
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
OBR Oncology
ASH2021
CAR-T
lymphoma
Yescarta
Tibsovo
blood cancers
COVID-19
AML
Flag link:
With fresh FDA nod, Servier branches targeted drug Tibsovo into bile duct cancer
With fresh FDA nod, Servier branches targeted drug Tibsovo into bile duct cancer
Fierce Pharma
Servier
Tibsovo
bile duct cancer
FDA
Flag link:
Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal
Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal
Pharmaforum
Servier
Agios
M&A
Tibsovo
AML
Flag link:
The 20 most expensive pharmacy drugs in the U.S. in 2020, from fallen blockbusters to new orphan meds
The 20 most expensive pharmacy drugs in the U.S. in 2020, from fallen blockbusters to new orphan meds
Fierce Pharma
drug pricing
Amryt Pharma
Myalept
Agios Pharmaceuticals
Tibsovo
Flag link:
ESMO: Agios celebrates milestone win for ivosidenib in tough-to-treat bile duct cancer
ESMO: Agios celebrates milestone win for ivosidenib in tough-to-treat bile duct cancer
Fierce Pharma
Agios
bile duct cancer
Tibsovo
ESMO
Flag link:
Agios Pharma's Tibsovo Shows Positive Results in Phase III for Another Cancer Indication
Agios Pharma's Tibsovo Shows Positive Results in Phase III for Another Cancer Indication
BioSpace
Agios Pharmaceuticals
Tibsovo
ivosidenib
clinical trials
cholangiocarcinoma
Flag link: